|
1
|
Szakàcs G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Holleman A, Cheok MH, den Boer ML, Yang W,
Veerman AJ, Kazemier KM, Pei D, Cheng C, Pui CH, Relling MV, et al:
Gene-expression patterns in drug-resistant acute lymphoblastic
leukemia cells and response to treatment. N Engl J Med.
351:533–542. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hulleman E, Kazemier KM, Holleman A,
VanderWeele DJ, Rudin CM, Broekhuis MJ, Evans WE, Pieters R and Den
Boer ML: Inhibition of glycolysis modulates prednisolone resistance
in acute lymphoblastic leukemia cells. Blood. 113:2014–2021. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP,
Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al: Overcoming
trastuzumab resistance in breast cancer by targeting dysregulated
glucose metabolism. Cancer Res. 71:4585–4597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Heiden MG Vander, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aghaee F, Pirayesh Islamian J and
Baradaran B: Enhanced radiosensitivity and chemosensitivity of
breast cancer cells by 2-deoxy-d-glucose in combination therapy. J
Breast Cancer. 15:141–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hua G, Liu Y, Li X, Xu P and Luo Y:
Targeting glucose metabolism in chondrosarcoma cells enhances the
sensitivity to doxorubicin through the inhibition of lactate
dehydrogenase-A. Oncol Rep. 31:2727–2734. 2014.PubMed/NCBI
|
|
9
|
Hamanaka RB and Chandel NS: Targeting
glucose metabolism for cancer therapy. J Exp Med. 209:211–215.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wei HL, Yao XJ, Li YN, Wang P, Zhao HS,
Bai DC, Peng X and Ma LF: Arsenic trioxide inhibits P-glycoprotein
expression in multidrug-resistant human leukemia K562/ADM cell line
that overexpresses mdr-1 gene and enhances their chemotherapeutic
sensitivity. Zhonghua Xue Ye Xue Za Zhi. 24:28–31. 2003.(In
Chinese). PubMed/NCBI
|
|
12
|
Cao X, Fang L, Gibbs S, Huang Y, Dai Z,
Wen P, Zheng X, Sadee W and Sun D: Glucose uptake inhibitor
sensitizes cancer cells to daunorubicin and overcomes drug
resistance in hypoxia. Cancer Chemother Pharmacol. 59:495–505.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Elstrom RL, Bauer DE, Buzzai M, Karnauskas
R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and
Thompson CB: Akt stimulates aerobic glycolysis in cancer cells.
Cancer Res. 64:3892–3899. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yeung SJ, Pan J and Lee MH: Roles of p53,
MYC and HIF-1 in regulating glycolysis-the seventh hallmark of
cancer. Cell Mol Life Sci. 65:3981–3999. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Manning BD and Cantley LC: AKT/PKB
signaling: Navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mungamuri SK, Yang X, Thor AD and
Somasundaram K: Survival signaling by Notch1: Mammalian target of
rapamycin (mTOR)-dependent inhibition of p53. Cancer Res.
66:4715–4724. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liang J and Mills GB: AMPK: A contextual
oncogene or tumor suppressor? Cancer Res. 73:2929–2935. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cerella C, Gaigneaux A, Dicato M and
Diederich M: Antagonistic role of natural compounds in
mTOR-mediated metabolic reprogramming. Cancer Lett. 356:251–262.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miller DM, Thomas SD, Islam A, Muench D
and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res.
18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan B, Piwnica-Worms D and Ratner L:
Multidrug resistance transporters and modulation. Curr Opin Oncol.
12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen J, Wei HL, Xie B, Wang B and Cheng J
and Cheng J: Endoplasmic reticulum stress contributes to arsenic
trioxide-induced apoptosis in drug-sensitive and -resistant
leukemia cells. Leuk Res. 36:1526–1535. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gatenby RA and Gillies RJ: Why do cancers
have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu PP and Sabatini DM: Cancer cell
metabolism: Warburg and beyond. Cell. 134:703–707. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hay N and Sonenberg N: Upstream and
downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu J, Blenis J and Yuan J: Activation of
PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by
phosphorylating and promoting the degradation of Mad1. Proc Natl
Acad Sci USA. 105:6584–6589. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pourdehnad M, Truitt ML, Siddiqi IN,
Ducker GS, Shokat KM and Ruggero D: Myc and mTOR converge on a
common node in protein synthesis control that confers synthetic
lethality in Myc-driven cancers. Proc Natl Acad Sci USA.
110:11988–11993. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Masui K, Tanaka K, Akhavan D, Babic I,
Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, et al: mTOR
complex 2 controls glycolytic metabolism in glioblastoma through
FoxO acetylation and upregulation of c-Myc. Cell Metab. 18:726–739.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Dang CV: MYC, metabolism, cell growth, and
tumorigenesis. Cold Spring Harb Perspect Med. 3:pii.a0142172013.
View Article : Google Scholar
|
|
29
|
Dang CV: The interplay between MYC and HIF
in the Warburg effect. Ernst Schering Found Symp Proc. 35–53.
2007.PubMed/NCBI
|
